Craft

Keros Therapeutics

Stock Price

$44.6

2024-06-17

Market Capitalization

$1.6 B

2024-06-17

Revenue

$151 K

FY, 2023

Keros Therapeutics Summary

Company Summary

Overview
Keros Therapeutics is a biotechnology company that develops therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta. It offers KER-050, an engineered ligand trap comprised of a modified ligand-binding domain; KER-012, which is designed to bind to and inhibit the signaling of ligands that stimulate the proliferation of vascular endothelial and smooth muscle cells and fibroblasts; and KER-065, that binds to and inhibits TGF-ß ligands, including myostatin (GDF8) and activin A.
Type
Public
Status
Active
Founded
2015
HQ
Lexington, MA, US | view all locations
Website
https://kerostx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jasbir Seehra
  • Christopher Rovaldi

    Christopher Rovaldi, Chief Operating Officer

  • Keith Regnante

    Keith Regnante, Chief Financial Officer

  • Esther Cho

    Esther Cho, Senior Vice President, General Counsel

    LocationsView all

    2 locations detected

    • Lexington, MA HQ

      United States

      1050 Waltham St Suite 302

    • South Wharf, VIC

      Australia

    Keros Therapeutics Financials

    Summary Financials

    Revenue (Q1, 2024)
    $83.0K
    Net income (Q1, 2024)
    ($43.1M)
    Cash (Q1, 2024)
    $442.4M
    EBIT (Q1, 2024)
    ($48.5M)
    Enterprise value
    $1.2B

    Footer menu